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1571 ABSTRACT 
The present invention relates to a container, system, and 
method for creating parenteral solutions at a site, remote 
from sterile environments. The system includes a flexible 
container that is empty except for a prepackaged amount of 
a solute that is housed in the interior of the container. The 
container includes at least one port and a sterilizing filter in 
communication with an interior of the port. The container is 
so constructed and arranged that a fluid flow path is created 
from the port through the filter and into the interior of the 
container. A sterile water source including means for estab- 
lishing fluid flow from the sterile water source into the port 
is provided. Accordingly, sterile water can flow from the 
sterile water source through the filter into the container 
where it is mixed with the solute to create a parenteral 
solution that can then be infused into a patient. A method and 
container are also provided. 
39 Claims, 1 Drawing Sheet 
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SYSTEM FOR CREATING AT A SITE, 
REMOTE FROM A STERILE 
ENVIRONMENT, A PARENTERAL 
SOLUTION 
BACKGROUND OF THE INVENTION 
The disclosed invention was funded, at least in part, by 
NASA. 
The present invention relates generally to the creation of 
solutions for intravenous administration. More specifically, 
the present invention relates to the creation on site, remote 
from sterile environments, of parenteral (intravenous) solu- 
tions. 
Of course, it is common practice to administer many 
solutions, medicaments, agents, and the like to a patient 
intravenously (parenterally). These solutions are typically 
housed in containers, that are constructed from flexible 
plastic or glass. Typically, these parenteral solutions are 
housed in containers having volume capacities of at least 
one liter, referred to as large volume parenteral containers. 
Large volume parenteral containers typically include 
solutions such as saline, dextrose, or lactated Ringer’s. 
Although these solutions can be administered to a patient 
alone, typically, an agent or medicament is added to the 
parenteral solution and the resultant product is then admin- 
istered intravenously to the patient. Accordingly, the con- 
tainer includes a medication or additive port allowing an 
agent to be added to the container. Additionally, an access 
port is provided for accessing the container. 
In use, the container is suspended and an IV line or other 
access means is utilized to access the container through the 
access port. Typically, the N line includes a spike that is 
designed to pierce a membrane in the access port establish- 
ing fluid communication. A second end of the IV line is then 
directly inserted into the patient or coupled to a Y-site that 
provides fluid communication with the patient. 
There are many situations wherein due to storage space 
and/or weight limitations, or other concerns, it is not pos- 
sible, or practical, to maintain an adequate inventory of 
parenteral solutions that may be necessary. For example, 
space shuttles, or the envisioned space stations, have severe 
restrictions on the weight and volume of items that are stored 
or transported. Although it may be desirable to stock a 
number of intravenous solutions for use in an emergency, or 
for medical treatment, it is not possible due to weight and/or 
storage limitations to inventory a large volume of such 
solutions in many situations. Likewise, in other situations, 
such as in a combat zone, it may not be possible to transport 
the necessary parenteral solutions. 
Still further, even within health care facilities, cost and 
storage limitations may limit the inventory of product that is 
purchased and stored. Therefore, it may be desirable to 
compound on the premises the necessary parenteral solu- 
tions. 
2 
Furthermore, typically reconstitution processes usually 
require either a prepackaged intravenous solution to assist in 
the reconstitution process, i.e., a bag of saline or dextrose, or 
can only be utilized to make small volumes of solutions. 
5 These processes therefore are not conducive to the creation 
of large volume parenteral containers. 
SUMMARY OF THE INVENTION 
The present invention relates to a container, system, and 
lo method for creating parenteral solutions at a site, remote 
from sterile environments. For example, it may be desirable 
in certain situations to create parenteral solutions immedi- 
ately prior to use due to limited storage space and/or weight 
The present invention provides such a system and method 
by providing a flexible container that is empty, except for a 
solute, and means for adding to the container sterile water so 
that the solute can be mixed with the sterile water to create 
20 a parenteral solution. Although the system and method can 
be used to create a parenteral solution that is then infused 
intravenously into a patient, the method for creating the 
parenteral solution can be performed in a nonsterile envi- 
ronment. 
To this end, a system for creating at a site, remote from a 
sterile environment, a parenteral solution in a large volume 
parenteral container is provided. The system includes a 
flexible container that is empty except for a prepackaged 
amount of a solute that is housed in the interior of the 
30 container. The container includes at least one port and a 
sterilizing filter in communication with an interior of the 
port. The container is so constructed and arranged that a fluid 
flow path is created from the port through the filter and into 
the interior of the container. A sterile water source including 
35 means for establishing fluid flow from the sterile water 
source into the port is provided. Accordingly, sterile water 
can flow from the sterile water source through the filter into 
the container where it is mixed with the solute to create a 
parenteral solution that can then be infused into a patient. 
In an embodiment, a system for creating at a site, remote 
from a sterile environment, a parenteral solution in a large 
volume parenteral container is provided. The system 
includes a flexible container including an interior that is 
empty except for a prepackaged amount of a solute. The 
45 interior of the container includes means for creating turbu- 
lence and a flow path within the interior. The container 
includes a sterile filter and a first port so constructed and 
arranged that fluid enters the first port and flows through the 
filter into the interior of the container. A source of sterile 
50 water including means for establishing fluid communication 
between the source of sterile water and the port is provided. 
Accordingly, a solute can be positioned within the container 
and sterile water can be injected, through the port and filter, 
into the container and due to the means for establishing 
55 turbulence and a fluid flow path, a mixing of the solute and 
water is achieved allowing a resultant parenteral solution to 
be created. 
15 considerations. 
25 
40 
Although it is known in certain applications to compound In an is andor reconstitute drugs prior to use, typically such recon- a powder. 
stitution processes are performed in sterile conditions, for 60 
example, under a laminar flow hood. Such sterile conditions In an embodiment of the present invention, the solute is 
would not typically be present in certain situations wherein a liquid ‘Oncentrate. 
there exists severe weight and storage limitations, e.g., the In an embodiment of the present invention, the solute 
aforementioned space station or combat zone. Likewise, includes a component Chosen from the group consisting Of: 
current machinery for creating large volume parenteral 65 dextrose; d i u m  chloride; and lactated Ringer’s. 
products not only require sterile conditions, but also is quite In an embodiment, a container is provided for reconsti- 
bulky and heavy and not easily transportable. tuting a parenteral solution. The container includes a flexible 
of the present invention, the 
5,484: 
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body defining an interior including means for creating 
turbulence and at least one fluid flow path within the interior 
of the container. A sterile filter is provided that is coupled to 
the container and is in fluid communication with a first 
opening that provides a fluid flow path between the filter and 5 
an interior of the container. A port in fluid communication 
with an end of the sterile filter is also provided. The 
container is so constructed and arranged that a fluid flow 
path is provided from the port, through the filter, through the 
The present invention also provides a method for creating 
parenteral solutions at a site remote from a sterile environ- 
ment. The method comprises the steps of: providing a 
flexible container that is empty except for a prepackaged 
solute; providing the flexible container with a port and 15 
sterilizing filter assembly; coupling the port to a sterile water 
source; allowing sterile water from the sterile water source 
to flow through the port and sterilizing filter into an interior 
of the container; and allowing the sterile water to mix with 
In an embodiment of the method, the solute is a powder. 
In an embodiment of the method, the solute is a liquid 
first opening and into the interior of the container. 10 
the solute to create a parenteral solution. 20 
,43 1 
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situations where weight and storage limitations present 
problems in maintaining sufficient inventories, e.g., space 
stations and combat zones. 
Referring now to FIG. 1, the system of the present 
invention includes a flexible container 10. The container 10 
includes a body 12 constructed from a flexible plastic 
material such as polyvinyl chloride, ethylene vinyl acetate, 
other polyolefins, or combinations thereof. Pursuant to the 
present invention, the container 10 is empty during storage 
except for a solute 11 that is located within the interior 13 of 
the container. 
The solute can be any composition that can create 
parenteral solutions. As used herein, a solute refers to a 
composition that when combined with water, or other fluid, 
creates a parenteral solution. For example, the solute can be 
sodium chloride, dextrose, or lactated Ringer’s. The solute 
can be in a liquid concentrate or powder form except in the 
case of lactated Ringer’s wherein the solute is preferably a 
liquid concentrate. Presently, due to sterilization techniques, 
the liquid concentrate form of the solute may be preferable. 
As discussed in more detail hereinafter, pursuant to the 
present invention, the solute is mixed with sterile water to 
create a parenteral solution. 
By way of example, the following solutes can be used to concentrate. 
In an m~bodiment of the method, the SolUte includes a 25 create one liter of a resultant parenteral solution when 
component Chosen from the group consisting of: dextrose; combined with sterile water. Liquid concentrate solutes 
sodium chloride; and lactated Ringer’s. include: 9 g/50 mL sodium chloride; 71.4 ml of 70% 
In an embodiment of the method, an agent is added to the dextrose; 40 mL of lactated Ringer’s concentrate B (5.94 gm 
resultant parenteral solution. sodium chloride, 0.297 mg potassium chloride, 0.198 mg 
In an embodiment of the method, the parenteral solution 30 calcium chloride dihydrate, 3.07 gm sodium lactate); and 50 
is administered intravenously to a patient. mL of lactated Ringer’s concentrate C (5.94 gm sodium 
Additional features and advantages of the present inven- 
tion are described in, and will be apparent from, the detailed 
description ofthe presently preferred embodiments and from 
0.297 mg potassium chloride, 0.198 mg calcium 
chloride dihydrate, 3.07 gm S d h m  lactate). Powder: 9 
grams ‘Odium chloride* for from Inter- 
35 national Salt; 45.5 grams dextrose anhydrous, for example, 
available from Corn Products; and 50 grams dextrose mono- 
hydrate, for example, available from Mallinkrodt. 
When mixed with approximately one liter of water, the 
solutes will create: saline, either normal or half normal, i.e., 
container of the present invention for creating at a site, 40 0.45% saline; dextrose, e.g., 5% dextrose; and lactated 
remote from a sterile environment, a parenteral solution. Ringer’s. These resultant solutions can then be intrave- 
nously administered to a patient. 
Located within the container 10, in the preferred embodi- 
ment illustrated, is an internal seal 14. The internal seal 14 
can be created in a number of ways, for example, by placing 
a plastic member between the two faces that define the body 
12 of the container 10 or sealing the two faces together at a 
predetennined area. The seal 14 defines two areas 20 and 22 
within the interior 13 of the container 10. Additionally, the 
seal 14 defines two gaps 16 and 18 within the interior 13 of 
the container 10 that allow fluid flow between the two areas 
20 and 22. 
Preferably, in use, the solute 11 is located in area 22. As 
discussed in more detail hereinafter, the seal 14 creates a 
flow path within the interior 13 of the container 10. The seal 
14 also functions to create turbulence when fluid flows into 
the container 10 ensuring an adequate mixing of the solute 
and sterile water that is used to create a parenteral solution 
within the container 10. 
As illustrated, preferably, the container 10 includes a 
plurality of ports. Of course, the container 10 can include 
any number of ports and although four ports are illustrated, 
a greater or lesser number of ports can be provided. 
In the illustrated embodiment, the container includes a 
first port 24 that functions as a medication port. The first port 
24 allows one to inject an agent or medicament into the 
the drawings. 
BRIEF DESCIUPTION OF THE DRAWINGS 
FIG. 1 illustrates a cross-sectional Perspective view of a 
FIG. 2 illustrates a cross-sectional perspective view of a 
parenteral solution being created in the container Of FIG. 1 
pursuant to the present invention. 
45 
DETAILED DESCRIPTION OF THE 
PRESENTLY PREFERRED EMBODIMENTS 
The present invention provides a container, system, and 
method for formulating a predetermined amount of a sterile 50 
solution by combining a premeasured, prepackaged amount 
of solute, that can be present either in a powder or liquid 
concentrate form, with a predetermined amount of sterile 
water. The solute is contained in a large volume parenteral 
container that is flexible so as to have a limited size and 55 
weight prior to formulation of the parenteral solution. 
Because the sterile water source can be any device that 
creates sterile water, from a nonsterile water source, this 
greatly reduces the weight and volume of the large volume 
parenteral containers that can be created as compared to 60 
typical prepackaged large volume parenteral containers. 
The present invention provides many advantages includ- 
ing that parenteral solutions can be created in a nonsterile 
environment. This allows the components necessary to cre- 
ate a variety of parenteral solutions to be easily transported 65 
and then used to create solutions as necessary. The advan- 
tages of such a system are limitless and include use in 
5,484,43 1 
5 
container. It is standard practice to inject a medicament or 
agent into a parenteral container including a parenteral 
solution so that the resultant solution and agent can then be 
infused into a patient. 
The first port 24 provides a means for providing access to 
the interior 13 of the parenteral container 10 so that an agent 
or medicament can be added. The parenteral container 10 
can be accessed through the first port 24 utilizing a variety 
of methods depending on the environments wherein the 
resultant product will be used. For example, it is known, in 
typical parenteral containers to use a syringe having a 
pointed cannula that is inserted through a resealable, pierce- 
able membrane that is located within an interior of the port. 
Likewise, access to the container can be through a needleless 
syringe and preslit injection site. Such a preslit membrane 
and cannula is disclosed in U.S. patent application Ser. No. 
07/147,414, “Preslit Injection Site and Associated Cannula” 
abandoned in favor of US. patent application Ser. No. 
07/539,278, the disclosure of which is incorporated herein 
by reference. The needleless syringe includes a cannula 
having a blunt end that is received within a preslit injection 
site. 
In the embodiment of the invention illustrated, the first 
port 24 includes, in an interior thereof, a one way valve that 
allows an agent to be injected into the interior of the 
container 10, but prevents fluid flow out of the container. An 
example of such a valve is the one way check valve 
produced by Burron Medical Corporation. The advantage of 
such a system that does not require a pointed cannula is with 
respect to trash disposable and accidental “sticks” that can 
occur with a pointed cannula. If desired, to allow fluid flow 
into and out of the container, a bidirectional valve, such as 
available from Burron Medical Corporation, can be used. 
The illustrated embodiment also includes a sterile port 
protector 25 or cap. The port protector 25 ensures the 
sterility of the interior of the first port 24 until it is desired 
to access the container 10 through the first port 24. Prefer- 
ably, to limit trash generation, the port protector 25 is 
tethered to the port 24. 
A second port 26 is provided that functions to allow one 
to access the fluid contained within the parenteral container 
10. To this end, the second port 26 is designed to receive a 
spike or other means for accessing the container. Typically, 
such a spike is a part of an administration set and can be used 
to administer intravenously the parenteral solution contained 
within the container 10 to a patient. Preferably, a bidirec- 
tional valve is used in the second port 26. Likewise, a port 
protector 27 is provided that is tethered to the second port 
26. 
A third port 28 is provided including a tethered port 
protector 29. The third port 28 is designed to allow a fluid 
such as sterile water to flow into the interior 13 of the 
container 10. To this end, the third port 28 includes means 
for allowing, as discussed in more detail hereinafter and 
illustrated in FIG. 2, a sterile water source 30 to be coupled 
to the third port 28 and provide fluid flow from the sterile 
water source through the third port 28. The third port 28 
terminates at and provides fluid communication with a 
sterilizing filter 32. Of course, the third port 28 and the filter 
32 can be integral and the same unit. Preferably, the third 
port includes a bidirectional valve. 
The sterilizing filter 32 is designed to sterilize fluid that 
flows from the third port 28 through the filter and then into 
the interior 13 of the container 10. For example, a 0.22 
micron sterilizing filter 32 can be utilized. Thus, a fluid flow 
path is provided from the third port 28 through the sterilizing 
filter 32 and into an interior 13 of the container 10. 
6 
In an embodiment, the sterilizing filter 32 is removably 
secured to the container 10. To this end, a h e r  connection or 
the like can be used to removably secure the filter to the 
container. This allows the sterile filter 32 to be removed after 
5 the parenteral solution has been created in the container. To 
accomplish this, a bidirectional valve can be located 
between the container and the filter so that when the filter is 
removed, fluid does not flow out of the container. 
The advantage of this structure, in part, is with respect to 
long term storage of the resultant parenteral solution con- 
taining containers. If stored for a long period of time, there 
is a potential for growth through the filter that could poten- 
tially contaminate the solution in the containers. 
Although a fourth port 34 is provided in the embodiment 
illustrated, the fourth port 34 is a redundant, extra port, and 
of course can be deleted if desired. The fourth port 34 
provides means for allowing a second agent to be introduced 
into the container or to provide other accessing requirements 
As previously stated, the system of the present invention 
also includes a sterile water source 30 that, as illustrated in 
FIG. 2, is designed to couple with the third port 28 and 
25 allows sterile water to be pumped through the third port 28 
and the filter 32 into the interior 13 of the container 10. 
When sterile water is so pumped it is passed through the 
sterilizing filter 32. 
Due to the construction of the interior 13 of the container 
30 10, and specifically, the seal 14, turbulence is created and a 
flow path 35 established through the area 22 up through the 
gap 18. Because the solute 12 is located in area 22, this 
causes a mixing of the sterile water and the solute creating 
the desired parenteral product within the interior 13 of the 
The sterile water source 30 can be any sterile water source 
that creates sterile water that is fed into the device. For 
example, the sterile water source 30 can be the Sterile Water 
for Injection System (SWIS), developed by the Sterimatics 
40 Division of Millipore Corporation for NASA. Such a system 
includes a particulate filter, activated charcoal filter, cation 
bed, anion bed and microbial filter. 
The system of the present invention allows parenteral 
45 solutions, such as dextrose solutions, saline, and lactated 
Ringer’s to be created that are ready to use. Even in the case 
of dextrose powders, it has been found that the dissolution 
rates of the powder are such that containers of parenteral 
solution can be created on an expedited basis. For example, 
5o assuming that the sterile water source 30 can produce no 
more than six liters of sterile water per hour, the fill time of 
a one liter parenteral container would be ten minutes. Ten 
minutes is sufficient time to dissolve the necessary dextrose 
powder allowing a 5% dextrose solution to be created that 
The sterile water source 30 can include a metering device 
(not shown) to ensure that only one liter of water is injected 
into the container, if a one liter solution is to be created. Of 
course, the metering device can also, if desired, be coupled 
60 to the container 10. Additionally, a clamshell or other 
structure (not shown) can be used that circumscribes the 
flexible container 10. The clamshell can be designed to only 
allow the container to accept a predetermined amount of 
fluid. 
By way of example and not limitation, projected weights 
and volume for the embodiments of the invention are as 
follows: 
10 
15 
2o and/or needs. 
35 flexible container 10. 
55 can then be administered intravenously. 
65 
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Approximate 
Approximate Approximate Approximate Weight 
Volume Weight Volume (Filled 
(Solute) (Solute) (Package) Package) 
Embodiment mL grams mL grams 
Powder in 1-liter bag 
Lactated Ringer’s - - - - 
Normal Saline 6.47 9.00 229.67 65.00 
Half-Normal Saline 3.24 4.50 229.67 69.50 
5% Dextrose 45.00 45.50 229.67 115.00 
Concentrate in 1-liter bag 
Lactated Ringer’s 40.00 47.7 229.57 120.00 
Normal Saline 50.00 58.10 229.67 120.33 
Half-Normal Saline 25.00 29.05 229.67 91.28 
5% Dextrose 71.40 91.60 229.67 157.67 
The above volumes and weights allow a number of 20 
possible parenteral solutions to be created as needed with a 
limited space and weight requirement. 
For example, based on the above, the system of the 
present invention provides the ability to make 120 one liter 
parenteral solutions, 30 each of 5% dextrose, normal saline, 25 
half-normal saline, and lactated Ringer’s using only the 
following volume and weight of components, exclusive of 
the sterile water source: 
30 
Weight Calculations 
1-Liter Bag - Powder 
5% Dextrxose 115.0 GramsNnit 3450 Grams 
Normal Saline 74.0 GramsNnit 2220 Grams 
Half-Normal Saline 69.5 GramsNnit 2085 Grams 
Lactated Ringer’s 120.0 GramsNnit 3600 Grams 
Total Weight 11355 Grams 
Volume Calculations 
1-Liter Bag - Powder 
5% Dextrose 229.7 mL 6890.10 mL 
Norml Saline 229.7 mL 6890.10 mL 
Half-Normal Saline 229.7 mL 6890.10 mL 
lactated Ringer’s 229.7 mL 6890.10 mL 
Total Volume 27560.40 mL 
Alternatively, if a liquid emcentrate is used: 
Weight Calculations 
5% Dextrose 
Norml Saline 
Ha l f -Nod  Saline 
Lactated Ringer’s 
5% Dextrose 
Normal Saline 
Half-Normal Saline 
Lactated Ringer’s 
1-LiterBag - Concentrate 
157.7 GramsAJnit 4791 Grams 
120.3 GramsNnit 3609 Grams 
91.3 GramsAJnit 2739 Grams 
120.0 GramsNnit 3600 Grams 
Total Weight 58720 Grams 
Volume Calculations 
1-Liter Bag - Concentrate 
229.7 mL 6890.10 mL 
229.7 mL 6890.10 mL 
229.7 mL 6890.10 mL 
229.7 mL 6890.10 mL 
Total Volume 27560.40 mL 
30.38% 
19.55% 
18.36% 
31.70% 
100.00% 
25.00% 
25.00% 
25.00% 
25.00% 
100.00% 
32.22% 
24.59% 
18.66% 
24.52% 
100.00% 
25.00% 
25.00% 
25.00% 
25.00% 
100.00% 
35 
40 
45 
50 
55 
By way of further example, one liter parenteral solutions 60 
can be created each of 120 dextrose, normal saline, half- 
normal saline, and lactated Ringer’s using only the follow- 
ing volume and weight of components: 
65 
Weight Calculations 
-continued 
1-Liter Bag - Powder 
5% Dextrose 115.0 GramsAJnit 13800 Grams 
Normal Saline 74.0 GramsNnit 8880 Grams 
Half-Normal Saline 69.5 GramsNnit 8340 Grams 
Lactated Ringer’s 120.0 GramslUnit 14400 Grams 
Total Weight 45420 Gram 
Volume Calculations 
1-Liter Bag - Powder 
5% Dextrose 229.7 mL 27560.40 mL 
Normal Saline 229.7 mL 27560.40 mL 
Half-Normal Saline 229.7 mL 27560.40 mL 
Lactated Ringer’s 229.7 mL 27560.40 mL 
Total Volume 110241.60 mL 
Alternatively, for a liquid concentrate solute: 
Weight Calculations 
1-Liter Bag - Concentrate 
5% Dextrose 157.7 GramslUnit 18920 Grams 
Normal Saline 120.3 GramsNnit 14440 Grams 
Half-Normal Saline 91.3 GramsNnit 10960 Grams 
Lactated Ringer’s 120.0 GramsNnit 14400 Grams 
Total Weight 58720 Grams 
Volume Calculations 
1-Liter Bag - Concentrate 
5% Dextrose 229.7 mL 27560.40 mL 
Normal Saline 229.7 mL 27560.40 mL 
Half-Normal Saline 229.7 mL 27560.40 mL 
Lactated Ringer’s 229.7 mL 27560.40 mL 
Total Volume 110241.60 mL 
30.38% 
19.55% 
18.36% 
31.70% 
100.00% 
25.00% 
25.00% 
25.00% 
25.00% 
100.00% 
32.22% 
24.59% 
18.66% 
24.52% 
100.00% 
25.00% 
25.00% 
25.00% 
25.00% 
100.00% 
Examples of methods of using the present invention are as 
follows: 
The flexible bag is preferably packaged in a foil pouch 
from which it is removed. The port protector from the inlet 
or third port that is coupled to the filter is removed. A sterile 
water source is connected to the container by coupling the 
outlet of the source to the inlet port on filter. The source 
begins to create sterile water and the flow of water is 
initiated from the water source into the interior of the 
container. Creating the sterile water and filling of the con- 
tainer will take approximately 10 minutes. 
The bag is allowed to fill. The bag is inspected at 
approximately 3 minute intervals for the presence of undis- 
solved powder. The bag is kneaded as required to dissolve 
the powder. No visible powder should remain after filling. 
The sterile water source is then disconnected from the 
container. The parenteral solution has now been created. 
5,484,43 1 
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If it is desired to add a medicament to the solution, in an 7. The system of claim 1 wherein the container includes 
embodiment, this can be accomplished as follows. A pre- at least one medication port and an administration port. 
filled syringe containing prescribed medication can be used. 8. The system of claim 1 wherein the parenteral solution 
Again, any means for injecting an additive into a parenteral created is chosen from the group consisting of: saline; 
container can be used. A port protector is removed from the 5 dextrose; and lactated Ringer’s. 
tip of prefilled syringe as well as the port protector from the 9. The system of claim 1 wherein the filter and the port are 
medication site. The syringe is connected to the medication integral. 
port, or first port. The medication is injected into the 10. The system of claim 1 wherein the filter is removably 
container. secured to the container. 
The port protector is removed from outlet or second port 11. A system for creating at a site, remote frorn a sterile 
of the container. The outlet port of the container is then environment, a parenteral Solution in a large volume 
connected to the inlet of an administration set. The set is parenteral container comprising: 
purged of air and then is connected to the patient; the flow a flexible container including an interior that is empty 
of the IV solution to the patient can then be accomplished. prior to adding a fluid except for a prepackaged amount 
of a solute and a means for creating turbulence wherein 
the forms a flow path 
within the interior, the container in fluid communica- wherein a concentrate is used, the method is substantially the 
same as set forth for the powder. The only difference is with tion with a sterilizing filter and a first port so con- 
respect to creating the solution which is as follows. structed and arranged that the fluid enters the port and 
Remove the bag from foil pouch. Remove the port pro- flows through the filter and into the interior of the 
tector from inlet port on filter. Connect the outlet of the 20 container; and 
sterile water source to inlet port on filter. Initiate flow of a source of sterile water including means for establishing 
water through the sterile water source. Filling will take fluid communication between the source of sterile 
approximately 10 minutes. Allow bag to fill. water and the port. 
Initial sterilization of the system can be accomplished for 12. The system of claim 11 wherein the solute is a powder. 
liquid concentrate embodiments using conventional tech- 25 13. The system of claim 11 wherein the solute is a liquid 
niques. To this end, the container 10 and solute can be concentrate. 
terminally sterilized. If powders are used, sterilization is 14. The system of claim 11 wherein the solute includes a 
difficult but it may be possible to terminally sterilize component chosen from the group consisting of: dextrose; sodium chloride; and lactated Ringer’s. 
ever, it is possible to manufacture the powder under sterile 30 tion created is from the group consisting of saline; 
conditions and then fill the container with powder under 
sterile conditions. 
fications to the presently preferred embodiments described 35 interior of the container. 
herein will be apparent to those skilled in the art. Such 
changes and modifications Can be made without departing 
from the spirit and scope of the present invention and 
without diminishing its attendant advantages. It is therefore 
intended that such changes and modifications be covered by 4o 
the appended claims. 
In an embodiment of the method of the present invention 15 for creating 
the container and Powder through gamma irradiation* How- 15. The system of claim 11 wherein the parenteral solu- 
dextrose; and lactated 
16. The system of claim 11 wherein the means for creating 
turbulence and the flow path is a seal located within the It should be understood that various changes and modi- 
17. The system of claim 11 wherein the container includes 
18. The system of claim 11 wherein the first port includes 
19. The system of claim 11 wherein the first port includes 
20. The system of claim 11 wherein the filter is removably 
21. A container for reconstituting a parenteral solution 
a flexible body having an interior that is empty prior to 
adding a fluid except for a prepackaged amount of a 
solute and a means for creating turbulence wherein the 
means for creating turbulence forms at least one fluid 
flow path within the interior, a sterilizing filter coupled 
to the container and in fluid communication with a first 
opening in the container allowing the fluid to flow from 
the filter into the interior of the container, and a port in 
fluid communication with an end of the sterilizing filter, 
the container being so constructed and arranged that 
fluid flow is from the port, through the filter, and into 
the interior of the container. 
22. The container of claim 21 wherein the solute is a 
powder. 
23. The container of claim 21 wherein the solute is a 
liquid concentrate. 
24. The container of claim 21 wherein the solute includes 
a component chosen from the group consisting of dextrose; 
sodium chloride; and lactated Ringer’s. 
25. The system of claim 21 wherein the means for creating 
turbulence and a flow path is a seal located within the 
interior. 
at least one medication port and an administration port. 
a one way valve. 
a bidirectional valve. 
coupled to the container. 
We claim: 
1. A system for creating at a site, remote from a sterile 
environment, a parenteral solution in a large volume 
parenteral container comprising: 45 comprising: 
a flexible container having an interior that is empty prior 
to adding a fluid except for a prepackaged amount of a 
solute that is housed in the interior of the container, the 
container including at least one port, and a sterilizing 
filter in fluid communication with the interior and the 50 
port, the container being so constructed and arranged 
that the fluid flows from the port, through the filter and 
into the interior of the container; and 
a source of sterile water including means for establishing 
fluid flow from the source of sterile water into the port. 55 
2. The system of claim 1 wherein the solute is a powder. 
3. The system of claim 1 wherein the solute is a liquid 
concentrate. 
4. The system of claim 1 wherein the solute includes a 
component chosen from the group consisting of dextrose; 60 
sodium chloride; and lactated Ringer’s. 
5. The system of claim 1 wherein the container includes 
means for defining at least two areas in the interior of the 
container that are in fluid communication. 
container includes a sealed portion that allows fluid flow 
across a bottom portion and a top portion of the seal. 
6.  The system of claim 1 wherein the interior of the 65 
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26. The container of claim 21 wherein the parenteral 
solution created is chosen from the group consisting of: 
saline; dextrose; and lactated Ringer’s. 
27. The container of claim 21 wherein the container 
includes at least one medication port and an administration 
port. 
28. The container of claim 21 wherein the port includes a 
one-way valve. 
29. The container of claim 21 wherein the port 10 includes 
a bidirectional valve. 
30. The container of claim 21 wherein the filter is remov- 
ably coupled to the container. 
31. The container of claim 21 wherein the means for 
creating turbulence and at least one fluid flow path defines 
two areas within the interior of the container, the solute 
being located in a first of the two areas. 
32. A method for creating parenteral solutions in large 
volume containers comprising the steps of: 
providing a flexible container having an interior that is 
empty prior to adding a fluid except for a prepackaged 
solute; 
providing the flexible container with a port outside the 
container and a sterilizing filter assembly in fluid 
communication with the interior of the container and 
the port; 
12 
allowing sterile water from the water source to flow 
through the filter into the interior of the container; and 
allowing the water to mix with the solute to create a 
parenteral solution. 
33. The method of claim 32 including the step of creating 
sterile water that is fed into the container from a nonsterile 
water source approximately contemporaneously with the 
flow of the water into the container. 
34. The method of claim 32 including the step of adding 
to the resultant parenteral solution a medicament. 
35. The method of claim 32 wherein the solute is a 
powder. 
36. The method of claim 32 wherein the solute is a liquid 
15 concentrate. 
37. The method of claim 32 wherein the solute includes a 
component chosen from the group consisting of: dextrose; 
sodium chloride; and lactated Ringer’s. 
38. The method of claim 32 wherein the parenteral 
solution created is chosen from the group consisting of: 
saline; dextrose; and lactated Ringer’s. 
39. The method of claim 32 including the step of remov- 
ing the filter from the container after creating the parenteral 
solution. 
5 
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* * * * *  coupling the port to a sterile water source; 
